MDT-AP-0815
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 39.96
- os_event
- false
- age_years
- 1.77
- sex
- F
- new_clusters
- S2
- umap1_2d
- -0.957346056
- umap2_2d
- -8.504440828
- umap1_3d
- -3.735513296
- umap2_3d
- -1.89855773
- umap3_3d
- 5.801837334
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.540
- ALLOGRAFT_REJECTION+0.500
- INFLAMMATORY_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- IL6_JAK_STAT3_SIGNALING+0.440
- COMPLEMENT+0.400
- KRAS_SIGNALING_UP+0.390
- APOPTOSIS+0.370
- COAGULATION+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.330
- DNA_REPAIR-0.250
- HEME_METABOLISM-0.230
- SPERMATOGENESIS-0.150
- MITOTIC_SPINDLE-0.140
- E2F_TARGETS-0.130
- G2M_CHECKPOINT-0.100
- PI3K_AKT_MTOR_SIGNALING-0.050
- HEDGEHOG_SIGNALING-0.010
- UV_RESPONSE_UP-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0410 | Med | Medulloblastoma | 0.908 |
| 2 | MDT-AP-2921 | Med | Medulloblastoma | 0.901 |
| 3 | MDT-AP-2377 | Med | Medulloblastoma | 0.895 |
| 4 | BS_55JW3HFM | Ganglioglioma | — | 0.892 |
| 5 | MDT-AP-2910 | Med | Medulloblastoma | 0.892 |
| 6 | BS_014EVM2D | low-grade glioma | — | 0.889 |
| 7 | MDT-AP-2902 | Med | Medulloblastoma | 0.888 |
| 8 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.886 |
| 9 | sclc1896_S36.txt | — | cohortMD2 | 0.882 |
| 10 | BS_JH29M4KG | pilocytic astrocytoma | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |